البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
SEMAGLUTIDE
NOVO NORDISK LTD., ISRAEL
A10BJ06
TABLETS
SEMAGLUTIDE 3 MG
PER OS
Required
NOVO NORDISK A/S, DENMARK
SEMAGLUTIDE
Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in combination with other medicinal products for the treatment of diabetes.
2021-02-17
Rybelsus IL PIL NOV23 – notification 1 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only RYBELSUS 3 MG RYBELSUS 7 MG RYBELSUS 14 MG TABLETS ACTIVE INGREDIENT: RYBELSUS 3 MG: EACH TABLET CONTAINS SEMAGLUTIDE 3 MG RYBELSUS 7 MG: EACH TABLET CONTAINS SEMAGLUTIDE 7 MG RYBELSUS 14 MG: EACH TABLET CONTAINS SEMAGLUTIDE 14 MG Inactive ingredients and allergens: see section 2 sub-section "Important information about some of this medicine’s ingredients ", and section 6 "Additional information". READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise: • as monotherapy – when metformin is considered inappropriate due to intolerance or contraindications. • in combination with other medicinal products for the treatment of diabetes. It is important that you continue with your diet and exercise plan as agreed with your doctor, pharmacist or nurse. THERAPEUTIC GROUP: Medicines for diabetes. GLP-1 (Glucagon-like peptide-1) analog. WHAT IS TYPE 2 DIABETES? Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin produced does not lower your blood sugar as required. In some cases, your body can produce too much blood sugar. If your blood sugar increases and remains high over a long period of time, this may lead to harmful effects such as heart problems, kidney disease, eye disorders and poor blood flow to the limbs. That is why it is important to keep your blood sugar levels اقرأ الوثيقة كاملة
Rybelsus IL SPC NOV23 - notification 1. NAME OF THE MEDICINAL PRODUCT Rybelsus (R) 3 mg Rybelsus (R) 7 mg Rybelsus (R) 14 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Rybelsus 3 mg Each tablet contains 3 mg semaglutide*. Rybelsus 7 mg Each tablet contains 7 mg semaglutide*. Rybelsus 14 mg Each tablet contains 14 mg semaglutide*. *human glucagon-like peptide-1 (GLP-1) analogue produced in _Saccharomyces cerevisiae_ cells by recombinant DNA technology. Excipient with known effect Each tablet, regardless of semaglutide strength, contains 23 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Rybelsus 3 mg tablets White to light yellow, oval shaped tablet (7.5 mm x 13.5 mm) debossed with ‘3’ on one side and ‘novo’ on the other side. Rybelsus 7 mg tablets White to light yellow, oval shaped tablet (7.5 mm x 13.5 mm) debossed with ‘7’ on one side and ‘novo’ on the other side. Rybelsus 14 mg tablets Rybelsus IL SPC NOV23 - notification White to light yellow, oval shaped tablet (7.5 mm x 13.5 mm) debossed with ‘14’ on one side and ‘novo’ on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in combination with other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1._ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The starting dose of semaglutide is 3 mg once daily for one month. After one month, the dose should be increased to a maintenance dose of 7 mg once daily. After at least one month with a dose of 7 mg once daily, the dose can be increased to a maintenance dose of 14 mg once daily to further improv اقرأ الوثيقة كاملة